vs

Side-by-side financial comparison of CBAK Energy Technology, Inc. (CBAT) and Ginkgo Bioworks Holdings, Inc. (DNA). Click either name above to swap in a different company.

CBAK Energy Technology, Inc. is the larger business by last-quarter revenue ($58.8M vs $33.4M, roughly 1.8× Ginkgo Bioworks Holdings, Inc.). On growth, CBAK Energy Technology, Inc. posted the faster year-over-year revenue change (131.8% vs -23.8%). CBAK Energy Technology, Inc. produced more free cash flow last quarter ($16.1M vs $-47.7M). Over the past eight quarters, CBAK Energy Technology, Inc.'s revenue compounded faster (-0.0% CAGR vs -6.2%).

CBAK Energy Technology, Inc. is a global supplier of lithium-ion battery products including high-performance cells, modules and battery packs. It serves key segments such as electric vehicles, stationary energy storage systems and consumer electronics, with core operations in China and a worldwide customer base.

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

CBAT vs DNA — Head-to-Head

Bigger by revenue
CBAT
CBAT
1.8× larger
CBAT
$58.8M
$33.4M
DNA
Growing faster (revenue YoY)
CBAT
CBAT
+155.6% gap
CBAT
131.8%
-23.8%
DNA
More free cash flow
CBAT
CBAT
$63.8M more FCF
CBAT
$16.1M
$-47.7M
DNA
Faster 2-yr revenue CAGR
CBAT
CBAT
Annualised
CBAT
-0.0%
-6.2%
DNA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CBAT
CBAT
DNA
DNA
Revenue
$58.8M
$33.4M
Net Profit
$-7.4M
Gross Margin
7.3%
Operating Margin
-13.6%
-211.9%
Net Margin
-12.5%
Revenue YoY
131.8%
-23.8%
Net Profit YoY
-63.6%
EPS (diluted)
$-0.08
$-1.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBAT
CBAT
DNA
DNA
Q4 25
$58.8M
$33.4M
Q3 25
$60.9M
$38.8M
Q2 25
$40.5M
$49.6M
Q1 25
$34.9M
$48.3M
Q4 24
$25.4M
$43.8M
Q3 24
$44.6M
$89.0M
Q2 24
$47.8M
$56.2M
Q1 24
$58.8M
$37.9M
Net Profit
CBAT
CBAT
DNA
DNA
Q4 25
$-7.4M
Q3 25
$2.7M
$-80.8M
Q2 25
$-3.1M
$-60.3M
Q1 25
$-1.6M
$-91.0M
Q4 24
$-4.5M
Q3 24
$17.6K
$-56.4M
Q2 24
$6.4M
$-217.2M
Q1 24
$9.8M
$-165.9M
Gross Margin
CBAT
CBAT
DNA
DNA
Q4 25
7.3%
Q3 25
8.0%
Q2 25
11.0%
Q1 25
13.7%
Q4 24
13.1%
Q3 24
15.6%
Q2 24
26.6%
Q1 24
31.9%
Operating Margin
CBAT
CBAT
DNA
DNA
Q4 25
-13.6%
-211.9%
Q3 25
-6.6%
-231.8%
Q2 25
-8.7%
-132.1%
Q1 25
-8.2%
-184.1%
Q4 24
-26.0%
-236.3%
Q3 24
-1.9%
-62.0%
Q2 24
12.4%
-396.7%
Q1 24
17.4%
-469.1%
Net Margin
CBAT
CBAT
DNA
DNA
Q4 25
-12.5%
Q3 25
4.4%
-207.9%
Q2 25
-7.6%
-121.6%
Q1 25
-4.5%
-188.2%
Q4 24
-17.8%
Q3 24
0.0%
-63.3%
Q2 24
13.5%
-386.4%
Q1 24
16.7%
-437.3%
EPS (diluted)
CBAT
CBAT
DNA
DNA
Q4 25
$-0.08
$-1.41
Q3 25
$0.03
$-1.45
Q2 25
$-0.03
$-1.10
Q1 25
$-0.02
$-1.68
Q4 24
$-0.05
$-1.91
Q3 24
$0.00
$-1.08
Q2 24
$0.07
$-4.23
Q1 24
$0.11
$-3.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBAT
CBAT
DNA
DNA
Cash + ST InvestmentsLiquidity on hand
$8.3M
$422.6M
Total DebtLower is stronger
$4.1M
Stockholders' EquityBook value
$112.7M
$508.6M
Total Assets
$426.2M
$1.1B
Debt / EquityLower = less leverage
0.04×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBAT
CBAT
DNA
DNA
Q4 25
$8.3M
$422.6M
Q3 25
$10.5M
$495.5M
Q2 25
$45.7M
$559.4M
Q1 25
$9.6M
$325.3M
Q4 24
$11.0M
$561.6M
Q3 24
$24.2M
$616.2M
Q2 24
$44.1M
$730.4M
Q1 24
$23.8M
$840.4M
Total Debt
CBAT
CBAT
DNA
DNA
Q4 25
$4.1M
Q3 25
$4.8M
Q2 25
$4.9M
Q1 25
$4.1M
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CBAT
CBAT
DNA
DNA
Q4 25
$112.7M
$508.6M
Q3 25
$121.4M
$559.8M
Q2 25
$118.2M
$613.0M
Q1 25
$120.8M
$647.4M
Q4 24
$121.7M
$716.1M
Q3 24
$131.2M
$797.9M
Q2 24
$126.6M
$833.1M
Q1 24
$120.9M
$987.3M
Total Assets
CBAT
CBAT
DNA
DNA
Q4 25
$426.2M
$1.1B
Q3 25
$363.9M
$1.2B
Q2 25
$333.1M
$1.2B
Q1 25
$311.5M
$1.3B
Q4 24
$302.2M
$1.4B
Q3 24
$293.5M
$1.5B
Q2 24
$279.6M
$1.6B
Q1 24
$286.5M
$1.6B
Debt / Equity
CBAT
CBAT
DNA
DNA
Q4 25
0.04×
Q3 25
0.04×
Q2 25
0.04×
Q1 25
0.03×
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBAT
CBAT
DNA
DNA
Operating Cash FlowLast quarter
$29.8M
$-47.7M
Free Cash FlowOCF − Capex
$16.1M
$-47.7M
FCF MarginFCF / Revenue
27.3%
-142.8%
Capex IntensityCapex / Revenue
23.4%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$3.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBAT
CBAT
DNA
DNA
Q4 25
$29.8M
$-47.7M
Q3 25
$14.6M
$-31.6M
Q2 25
$13.8M
$-40.3M
Q1 25
$-9.6M
$-51.5M
Q4 24
$9.6M
$-42.4M
Q3 24
$19.7M
$-103.5M
Q2 24
$2.9M
$-84.4M
Q1 24
$7.4M
$-89.3M
Free Cash Flow
CBAT
CBAT
DNA
DNA
Q4 25
$16.1M
$-47.7M
Q3 25
$6.0M
Q2 25
$4.1M
$-40.3M
Q1 25
$-22.3M
$-59.1M
Q4 24
$3.9M
$-56.1M
Q3 24
$16.5M
$-118.6M
Q2 24
$2.5M
$-111.4M
Q1 24
$-454.0K
$-96.0M
FCF Margin
CBAT
CBAT
DNA
DNA
Q4 25
27.3%
-142.8%
Q3 25
9.9%
Q2 25
10.2%
-81.2%
Q1 25
-63.9%
-122.4%
Q4 24
15.5%
-128.0%
Q3 24
37.1%
-133.2%
Q2 24
5.2%
-198.2%
Q1 24
-0.8%
-252.9%
Capex Intensity
CBAT
CBAT
DNA
DNA
Q4 25
23.4%
0.0%
Q3 25
14.1%
0.0%
Q2 25
23.8%
0.1%
Q1 25
36.3%
15.8%
Q4 24
22.5%
31.3%
Q3 24
7.0%
16.9%
Q2 24
0.9%
48.1%
Q1 24
13.4%
17.7%
Cash Conversion
CBAT
CBAT
DNA
DNA
Q4 25
Q3 25
5.51×
Q2 25
Q1 25
Q4 24
Q3 24
1115.72×
Q2 24
0.46×
Q1 24
0.76×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CBAT
CBAT

Manufacturing Lithium Batteries$28.0M48%
Residential Energy Supply And Uninterruptable Supplies$17.8M30%
Light Electric Vehicles$12.9M22%
Precursor$108.0K0%

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

Related Comparisons